p53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 264-268

  Dahiya, R ^a   Deng, G ^a   Chen, K M K ^a   Chui, R M ^a   Haughney, P C ^a   Narayan, P ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

p53 mutation; Polymerase chain reaction; Prostate cancer; Single strand conformation polymorphism

Indexed keywords

PROTEIN P53;

ARTICLE; EXON; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0030015730     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.349     Document Type: Article

References (33)

1. BAKER SJ, MARKOWITZ S, FEARON ER, WILSON JKV AND VOGELSTEIN B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249, 912-915.
2. CARTER BS, EWING CM, WARD WS, TREIGER BF, AALDERS TW, SCHALKEN JA, EPSTEIN JI AND ISAACS WB. (1990). Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl Acad. Sci., 87, 8751-8755.
3. CHEN P-L, CHEN Y, BOOKSTEIN R AND LEE W-H. (1990). Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250, 1576-1582.
4. CLORE GM, OMICHINSKI JG, SAKAGUCHI K, ZAMBRANO N, SAKAMOTO H, APPELLA E AND GRONENBORN. (1994). High-resulation structure of the oligomerization domain of p53 by multidimensional NMR. Science, 265, 386-394.
5. DAHIYA R, ITZKOWITZ SH, BYRD JC AND KIM YS. (1989). ABH blood group antigen expression, synthesis and degradation in human colonic adenocarcinoma. Cancer Res., 49, 4550-4556.
6. DAHIYA R, ITZKOWITZ SH, BYRD JC AND KIM YS. (1992). Mucin oligosaccharide biosynthesis in human colon cancer tissues and cell lines. Cancer, 70, 1467-1476.
7. DAHIYA R, ZHANG DY, HO RJ, HAUGHNEY PC, HAYWARD SW, CUNHA GR AND NARAYAN P. (1995a). Regression of LNCaP human prostate tumor xenograft in athymic nude mice by 13-cis-retinoic acid and androgen ablation. Biochem Mol. Biol. Inter., 35, 487-498.
8. DAHIYA R, DENG G, CHEN K, HAUGHNEY PC, CUNHA GR AND NARAYAN P. (1995b). New approach to hot-start polymerase chain reaction using Taq DNA polymerase antibody. Urol. Oncol., 1, 42-46.
9. DINJENS WNM, VANDER WEIDEN MM, SCHROEDER FH, BOSMAN FT AND TRAPMAN J. (1994). Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int. J. Cancer, 56, 630-633.
10. DONEHOWER LA, HARVEY M, SLAGLE B, MCARTHUR MJ, MONTGOMERY JR CA, BUTEL JS AND BRADLEY A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature, 365, 215-221.
11. DULIC V, KAUFMANN WK, WILSON SJ, TLSTY TD, LEES E, HARPER JW, ELLEDGE SJ AND REED SI. (1994). p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76, 1013-1023.
12. DUTTA A, RUPPERT JM, ASTER JC AND WINCHESTER E. (1992). Inhibition of DNA replication factor RPA by p53. Nature, 365, 79-82.
13. ELIYAHU D, MICHALOVITZ D, ELIYAHU S, PINHASI-KIMHIO AND OREN M. (1989). Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl Acad. Sci. USA, 86, 8763-8767.
14. FINLAY CA, HINDS PW, AND LEVINE AJ. (1989). The p53 protooncogene can act as a suppressor of transformation. Cell, 57, 1083-1093.
15. GAO X, ZACHAREK A, SALKOWSKI A, GRIGNON DJ, SAKR W, PORTER AT AND HONN KV. (1995). Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res., 55, 1002-1005.
16. HARRIS CC AND HOLLSTEIN MC. (1993). Clinical implications of the p53 tumor suppressor gene. N. Engl. J. Med., 328, 1318-1327.
17. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B AND HARRIS CC (1991). P53 mutation in human cancers. Science, 253, 492-495.
18. ISAACS WB, CARTER BS AND EWING CM. (1991). Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 51, 4716-4720.
19. KERN SE, PIETENPOL JA, THIAGALINGAM S, SEYMOUR A, KINZLER KW AND VOGELSTEIN B. (1992). Oncogene forms of p53 inhibited p53-regulated gene expression. Science, 256, 827-830, 1992.
20. MACK DH, VARTIKAR J, PIPAS JM AND LAIMINS LA. (1993). Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature, 363, 281-283.
21. MALKIN D, LI FP, STRONG LC, FRAUMENI JF, NELSON CE, KIM DH, KASSEL J, GRYKA M, BISCHOFF FZ, TAINSKY MA AND FRIEND SH. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1223-1238.
22. MIETZ JA, UNGER T, HUIBREGTSE JM AND HOWLEY PM. (1992). The transcriptional activation function of wild-type p53 is inhibited by SV40 large T antigen and by HPV-16 E6 oncoprotein. EMBO J., 11, 5013-5020.
23. MIYASHITA T, HARIGAI M, HANADA M AND REED JC. (1994). Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54, 3131-3135.
24. MULLINS KB AND FALOONA F. (1987). Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol., 155, 335-350.
25. NAVONE NM, TRONCOSO P, PISTERS LL, GOODROW TL, PALMER JL, NOCHOLS WW, VON ESCHENBACH AC AND CONTI CJ. (1993), p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl Cancer Inst., 85, 1657-1669.
26. PEEHL DM. (1993). Oncogenes in prostate cancer. Cancer, 71, 1159-1164.
27. SCHARER E AND IGGO R. (1992). Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res., 20, 1539-1545.
28. SHARKEY D, SCALICE E, CHRISTRY K, ATWOOD SM AND DAISS JL. (1994). Antibodies as thermolabile switches: high temperature triggering for the polymerase chain reaction. Biotechnology, 12, 506-509.
29. THOMPSON SJ, MELLON K, CHARLTON RG, MARSH C, ROBINSON M AND NEAL DE. (1992). p53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br. J. Urol., 69, 609-613.
30. VAN VELDHUIZEN PJ, SADASIVAN R, GARCIA F, AUSTENFELD MS AND STEPHENS RL. (1993). Mutant p53 expression in prostate carcinoma. The Prostate, 22, 23-30.
31. VISAKORPI T, KALLIONIEMI OP, HEIKKINEN A, KOIVULA T AND ISOLA J. (1992). Small sub-group of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl Cancer Inst., 84, 883-887.
32. VOGELSTEIN B AND KINZLER KW. (1992). p53 function and dysfunction. Cell, 70, 523-526.
33. XIONG Y, HANNON GJ, ZHANG H, CASSO D, KOBAYASHI R AND BEACH D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-711.